Recent studies have recently questioned the current role of β-blockers in myocardial infarction. Our purpose is to analyze the influence of the previous use of β-blockers on the early course of patients admitted because of acute coronary syndrome (ACS). We analyzed the data of 37.359 patients included in the ARIAM-Andalucia Registry. Of them, 7759 (20.8%) were previously receiving β-blockers. BB patients were older, more often female, had more risk factors and vascular disease, and less often had an ST-elevation myocardial infarction. In the unadjusted analysis, BB patients less often had ventricular fibrillation or atrioventricular block, and more often a Killip classification >1, and no difference of in-hospital mortality (5.7 vs 5.6%). After logistic regression analysis and propensity score matching, no differences in complications or mortality (odds ratio 0.997, 95% confidence interval 0.882-1.128) were found in relationship to previous β-blockers. In conclusion, we find that the previous administration of β-blockers is not an independent predictor of the early prognosis of ACS.
Introduction
Tachycardiomyopathy is a common cause of left ventricular systolic dysfunction (LVSD), whose complete resolution after arrhythmia control is highly variable among patients.
Purpose
To assess the associated factors with complete left ventricular reverse remodeling (CLVRR) in patients with confirmed tachycardiomyopathy.
Methods
Retrospective single-centre, observational study of consecutive patients with diagnosed tachycardiomyopathy between January 2015–2022. CLVRR was defined by a recovered left ventricular ejection fraction (RLVEF) >55% and a left ventricular end-dyastolic diameter (LVEDD) <55 mm assessed by transthoracic echocardiography.
Results
134 patients were gathered in this period. Patients with previous known LVSD or LV dilatation were excluded from the analysis (n=6). Baseline characteristics are displayed in Image 1. Most frequent arrhythmia was atrial fibrillation (73.8%), followed by atrial flutter (25.4%), atrial tachycardia (2.2%) and ventricular extrasystole (5.2%). 99.2% of patients were treated with beta-blockers, 71.6% with ACEI/ARBs, 23.9% with neprilysin inhibitors and 64.2 with aldosterone receptor antagonist. Rhythm control was achieved in 82.1% of patients, of whom 80% underwent an ablation procedure after a mean of 8.2 months. After 10.8 months since LVSD, mean RLVEF was 55.4% (+6.3) and mean LVEDD 52.1 mm (+5.8). CLVRR was observed in 50% of patients. A multivariate analysis was performed in a stepwise fashion to assess associated factors, including baseline information (medical history, echocardiographic information and received treatment, both pharmacological and ablation). CLVRR was associated with female-sex (coefficient 1.18; p=0.009) and severe baseline left ventricular disfunction (coefficient −0.80; p=0.041), corrected by previous alcohol abuse history (coefficient 0.94; p=0.055) and a rhythm-control strategy (coefficient 0.98; p=0.052) which didn't reach complete statistical significance.
Conclusion
Women, patients without severe LV dysfunction at baseline, with history of previous alcohol abuse and receiving a rhythm-control strategy were associated with a complete left ventricular reverse remodeling in patients with tachycardiomyopathy.
Funding Acknowledgement
Type of funding sources: None.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.